N/A N=267 A Trial of Two Family-based Childhood Obesity Treatment Programs
Obesity, Childhood
Primary: Change From Baseline in Child Body Mass Index (BMI) Z-score at 6 Months — 0.03; 0.00 z-scores
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Metabolic Syndrome and Fall Risk
Metabolic Syndrome · Autonomic Neuropathy
Primary: Four Square Step Test (FSST) — 11.04; 14.29 seconds
Phase 2 N=54 Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
Asthma, Aspirin-Induced
Primary: Change From Baseline in Sinonasal Outcome Test-22 Score — -6.7; -13.7 units on a scale
N/A N=666 Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake
SARS-CoV2 Infection
Primary: Number (Percentage) of Participants Requested to Participate in Saliva-based SARS-CoV-2 Antibody Testing — 175; 84; 121 Participants
Phase 2 N=87 A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection
Cytomegalovirus Disease
Primary: Incidence of CMV Disease or CMV Viremia — 29; 9; 26 Participants
Phase 3 N=155 Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men
Hypogonadism, Male
Primary: Change From Baseline in 24-hour Average Ambulatory Systolic Blood Pressure After 120 Days Treatment — 128.9; 130.6; 1.7 mmHg
Phase 3 N=99 Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Mycobacterium Infections, Nontuberculous
Primary: Psychometric Cross-Sectional Validation of Patient Reported Outcome (PRO): Patient Global Impression of Severity (PGI-S) Respiratory Scale Score at Baseline — 2.5; 2.4…
Phase 2 N=16 Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Locally Advanced Head and Neck Squamous Cell Carcinoma
Primary: Number of Participants Who Successfully Completed Planned Treatment — 15 Participants
N/A N=109 Weight Loss Treatment for Veterans With Binge Eating
Binge Eating Disorder
Primary: Change in Eating Disorder Examination-Self-report Questionnaire (EDE-Q) — 3.18; 2.89; 2.81; 2.13 score on a scale
Phase 2 N=140 Repurposing Anti-TNF for Treating Dupuytren's Disease
Dupuytren's Disease
Primary: Early Disease: Nodule Hardness at 12 Months — 58.1; 61.2 Durometer Arbitrary Units (AU)
Phase 3 N=108 Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
Malignant Neoplasm of Breast
Primary: Pathologic Complete Response — 18; 15 Participants — p=0.73
Phase 2 N=186 Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone
Non Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 10.9; 10.9 Month — p=0.124
Phase 3 N=30 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
Prostate Cancer · Prostatic Neoplasm · Prostatic Neoplasms, Castration-Resistant
Primary: Sensitivity of Ga 68-labeled PSMA-11 Positron Emission Tomography/Computed Tomography (PET/CT) for the Detection on a Per Patient Basis — 1.0 proportion of participants
Phase 2 N=24 A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Rhabdomyosarcoma · Melanoma
Primary: Average Number of Lymph Nodes Identified Intraoperatively Per Subject — 3.30 nodes per subject
N/A N=125 Parental Perceptions on Prescription Opioid Use
Orthopedic Disorder
Primary: Comfort With Child Receiving Opioids During Surgery — 5; 84; 36 Participants